Malignant pleural effusion (MPE) is one of the most common metastases in Non-Small Cell Lung Carcinoma (NSCLC). Some part of the pleural fluid analysis affects the patient's survival. A retrospective cohort study using medical record data of 76 patients was done in Prof. Dr. IGNG Ngoerah General Hospital. The one-year survival was 36.6%, with a median survival of 240 days or 8 months (95% CI 110.94–369.05). The cut-off point for pleural fluid protein was 5 g/dL (sensitivity 33.3%, specificity 32.1%), glucose 47.5 mg/dL (sensitivity 81.3%, specificity 32.1%), lactate dehydrogenase (LDH) 978.5 IU/L (sensitivity 41.7%, specificity 46.4%) and pH 7.3 (sensitivity 62.5%, specificity 35.7%). Bivariate analysis showed that only protein was associated with survival. Protein < 5 g/dL had a median survival of 116 days (95% CI 67.96 – 164.05, p = 0.001). Multivariate analysis showed pleural fluid protein < 5gr dL, best supportive care therapy, and non-adenocarcinoma histology were independent risk factors for death {HR 2,345,95% CI: 1,055-5,214; p= 0.037; HR 5,332. 95% CI: 2.109 – 13.478; p = 0.000; HR 2,635, 95% CI 1,096 – 6,335; p = 0.30).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.